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The action of type I interferons in the central nervous
system (CNS) during autoimmunity is largely un-
known. Here, we demonstrate elevated interferon
beta concentrations in the CNS, but not blood, of
mice with experimental autoimmune encephalomy-
elitis (EAE), a model for CNS autoimmunity. Further-
more, mice devoid of the broadly expressed type I
IFN receptor (IFNAR) developed exacerbated clinical
disease accompanied by a markedly higher inflam-
mation, demyelination, and lethality without shifting
the T helper 17 (Th17) or Th1 cell immune response.
Whereas adoptive transfer of encephalitogenic T cells
led to enhanced disease in Ifnar1/ mice, newly cre-
ated conditional mice with B or T lymphocyte-specific
IFNAR ablation showed normal EAE. The engage-
ment of IFNAR on neuroectodermal CNS cells had
no protective effect. In contrast, absence of IFNAR
on myeloid cells led to severe disease with an en-
hanced effector phase and increased lethality, indi-
cating a distinct protective function of type I IFNs
during autoimmune inflammation of the CNS.
INTRODUCTION
Multiple sclerosis (MS) is considered to be an inflammatory
demyelinating disease of the central nervous system (CNS),
and its etiology remains unclear (Steinman, 1996). This condition
is represented in the well-established animal model for brain
inflammation and MS, known as experimental autoimmune en-
cephalomyelitis (EAE), which is a vital tool to study the neuroim-
munological events related to the disease (Owens et al., 2001)
and resembles many facets of MS (Gold et al., 2006).Therapeutic application of interferon gamma (IFN-g) induced
acute relapses in MS patients (Panitch et al., 1987), supporting
the notion that proinflammatory T helper type 1 (Th1) cell cyto-
kines play a crucial role in the immunopathogenesis of MS. In
contrast, the type I interferon beta (IFN-b) reduces the frequency
of clinical exacerbations by about 35% and delays the progres-
sion of disability in relapsing-remitting MS. Similarly, the lack
of the IFN-b gene in mice strongly enhanced the course of EAE
(Teige et al., 2003), and type I interferons can downregulate
EAE in mice and rats (Brod and Khan, 1996; Brod and Burns,
1994), indicating that IFN-b modulates the disease activity in
MS and EAE in a similar fashion.
Regarding the underlying mechanism, earlier studies have
suggested several possibilities, including inhibition of Th1 cell
development (McRae et al., 1998), induction of Th2 cell immune
deviation (Kozovska et al., 1999), restoration of function of the
disrupted blood-brain barrier (Stone et al., 1995), and downregu-
lation of IFN-g-induced expression of class II major histocom-
patibility complex (MHC) molecules on CNS cells (Satoh et al.,
1995). In the light of recent data on IFN-b-induced gene profiles
(Satoh et al., 2006; Wandinger et al., 2001), however, it is gener-
ally accepted that IFN-b reveals extremely complex actions that
cannot only be reduced to a simple Th2 cell shift (Frohman et al.,
2006).
To date, therapeutic intervention using IFN-b is a major treat-
ment option for MS. However, in up to one-third of the cases, the
efficiacy of IFN-b therapy ceases after one year, partly because
of the fact that many of these patients develop autoantibodies
against IFN-b (Waubant et al., 2003). Furthermore, a substantial
proportion of the patients discontinue IFN-b treatment because
of multiple serious side effects, such as skin reactions, flu-like
symptoms, leukocytopenia, liver dysfunction, depression, elevated
suicide rate, and amenorrhea (Neilley et al., 1996).
These adverse effects stress the need to better understand
how IFN-b actually functions on the molecular and cellular level
in an in vivo setting. Previous studies relied on simplified in vitroImmunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 675
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IFNAR and CNS Autoimmunityexperiments. Progress with the EAE model, on the other hand,
was hampered by the fact that the respective receptor of type
1 interferons (IFN-as and IFN-b), IFNAR, is broadly expressed
by virtually all cell types and tissues, including immune cells
(Pogue et al., 2004), endothelial cells (Floris et al., 2002), and
CNS-resident neurons and glia (Okada et al., 2005; Heine
et al., 2006).
To identify the actual cell type targeted by disease-associated
IFN-b locally produced in the brain, we conditionally deleted
IFNAR from the CNS, lymphocytes, or myeloid cells and studied
the pathogenesis of CNS autoimmunity in such mice. Our inves-
tigations provide insights into disease-limiting mechanisms that
might open new avenues to more cell-specific IFN-b-based ther-
apies minimizing severe adverse effects. Despite being broadly
expressed, INFAR was determined to have a unique role on
myeloid cells for modulating CNS autoimmunity.
RESULTS
Local IFN-b Production and IFNAR Signaling
within the CNS during Autoimmunity
We first assessed endogenous IFN-b production in the CNS and
blood of MOG35–55 immunized mice by an enzyme-linked immu-
noabsorbent assay (ELISA) method on day 7, when animals were
still free of disease symptoms (score 0), and on day 18, when
animals presented with full EAE symptoms (scores > 1.5). Sick
individuals showed increased amounts of IFN-b levels in the
CNS, whereas IFN-b in the blood of both groups was below
the detection limit (Figure 1A).
To assess IFNAR signaling triggered by endogenously pro-
duced IFN-b, we extracted total RNA from the spinal cord of
healthy (score0),moderatelysick (scores 0.5–1.5), and severelyaf-
fected (scores > 2.5) mice and monitored the expression of IFNAR-
dependent genes by RNA blotting. Even in moderately sick mice,
enhanced hybridization signals were found for interferon regula-
tory factor 1 (IRF1), interferon regulatory factor 7 (IRF7), interferon
stimulated gene 15 (ISG 15), and 20,50oligoadenylatsynthetase
(20,50OAS) (Figure 1B). Collectively, these data indicate that even
at the onset of the first clinical symptoms, when leukocyte influx
can first be monitored, IFN-b is produced locally in the brain in
biologically relevant quantities.
Disease-Modulating Role of IFNAR during
the Effector Phase of EAE
To examine the impact of IFNAR signaling on the disease course
of EAE, we immunized Ifnar1/ and wild-type (WT) mice. All
animals developed EAE with an incidence of 100% and a similar
mean disease onset (Table S1 available online). However, in
Ifnar1/ animals, the effector phase of disease was changed
dramatically, with an increased lethality rate and an augmented
mean maximal clinical score (Figure 2A, Table S1, Movies S1
and S2).
IFNAR-deficient spinal cords showed histologically at 35 days
after immunization a plethora of infiltrating MAC-3+ macro-
phages and microglia in the submeningeal and perivascular
space, as well as in the CNS parenchyma, which were, upon
quantification of the histological sections, significantly upregu-
lated (p < 0.05) (Figures 2B and 2C right panel). Importantly,
this increased influx of macrophages was accompanied by an676 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.invasion of numerically unchanged CD3+ lymphocytes. The my-
elin damage, however, was increased in Ifnar1/ animals
(Figure 2C, left panel, p < 0.05). This distinct pathological infiltra-
tion reflected clinical characteristics of Ifnar1/ mice showing
increased disease burden.
Th17 cells are now widely believed to be the main pathogenic
population during autoimmune CNS inflammation (Steinman,
2007). We therefore quantified interleukin-17 (IL-17)-producing
myelin oligodendrocyte glycoprotein (MOG)-reactive T cells in
Figure 1. CNS-Endogenous Induction of IFN-b and IFNAR Signaling
during Autoimmune Disease
(A) Measurement of IFN-b production in the CNS (gray bars) and blood sam-
ples (black bars) of immunized, nonsick animals (score 0) or sick animals
(score > 1.5). Data represent the means out of four animals in each group ±
the standard error of the mean (SEM).
(B) RNA blot analysis showing disease-associated induction of IFNAR-depen-
dent genes in the CNS of eight individual mice that are either healthy (immu-
nized, score 0), slightly (score 0.5–1.5) or severely EAE sick (score > 2.5).
IFNAR-induced genes were interferon regulatory factor 1 (IRF1), interferon reg-
ulatory factor 7 (IRF7), 20-50 oligoadenylatsynthetase (20,50 -OAS), and inter-
feron-stimulated gene 15 (ISG15).
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IFNAR and CNS Autoimmunitythe CNS at day 14 as well as in lymph node cells at days 7 and 14
(Figure 2D, Figure S1). Enzyme-linked immunospot analysis did
not show any apparent changes in the IL-17, IL-4, and IFN-g
profiles in antigen-specific T cells. For further determination of
the impact of IFNAR expression on the cytokine profile within
the CNS, mice were sacrificed at the disease peak, and expres-
sion of chemoattractant factors and cytokines were examined by
real-time polymerase chain reaction (PCR) (Figure 2E). Despite
a trend toward generally elevated amounts of cytokines in
IFNAR-deficient mice, IFN-g, IL-12p35, STAT6, IL-13, TGF-b1,
IL-6, and IL-23p19 were not significantly increased, suggesting
that more severe EAE in the absence of IFNAR is not linked to
a certain Th1, Th2, or Th17 cell bias throughout the disease
course. In contrast, chemokines recruiting monocytes and
macrophages such as CCL2 and CXCL10 were found to be
increased in Ifnar1/ mice (p < 0.05). These data revealed that
IFNAR is important for the modulation of the effector phase of
autoimmunity, and its absence facilitates macrophage invasion
into the CNS accompanied by higher demyelination and produc-
tion of chemokines without shifting the T cell profile.
CNS-Specific IFNAR Expression Is Dispensable
for the Induction and Progression of EAE
To assess the role and function of IFNAR during the EAE effector
phase, which essentially occurs within the CNS, encephalito-
genic MOG-reactive lymphocytes were isolated from WT mice
and adoptively transferred into either WT or Ifnar1/ recipient
mice. Ifnar1/ mice developed EAE with earlier disease onset
and increased severity, as well as higher incidence rate (p <
0.05, Figure 3 and Table S2). These data indicate that IFNAR is
involved in the local maintenance of encephalitogenicity during
the effector phase of EAE within the CNS.
To determine whether IFNAR engagement of CNS-resident
cells limits the progression of autoimmune inflammation,
we crossed conditional (floxed) IFNAR mice with a transgenic
mouse line expressing the Cre recombinase under the control
of the nestin promoter. Southern-blot analysis of DNA isolated
from different tissues of an Ifnar1fl/fl NesCre mouse showed effi-
cient deletion of the gene fragment flanked by loxP in the CNS
tissue and isolated astrocytes, whereas recombination was
absent in the spleen and in primary microglia (Figure 4A).
Upon immunization, all Ifnar1fl/fl NesCre mice developed neu-
rological signs of disease such as tail weakness and paralysis,
starting about 13–16 days after immunization. (Figure 4B, Table
S3), indicating that the priming phase of disease was unaltered.
Furthermore, the mean maximal scores were similar in both
groups, suggesting that IFNAR expression on CNS cells is dis-
pensable in EAE. Examination of the CNS revealed no obvious
differences in either the pattern of mononuclear infiltration or
the amount of macrophages or microglia, and T lymphocytes
(Figure 4C). Because the Cre transgene is active in all neuroec-
todermal cells, we also examined disease-associated pathology
in axons (Figure 4D), oligodendrocytes (Figure 4E), and astro-
cytes (Figure 4F) and found no marked changes (Figures 4D–
4F). Overall, these data indicated that the brain-specific IFNAR
is not an essential modulator of the degree and composition of
inflammation, demyelination, and axonal damage during sterile
autoimmune CNS disease.IFNAR Engagement on Lymphocytes Has No Impact
on T Cell Priming or EAE Development
We further studied the direct impact of IFN-b on lymphocytes in
mice with a T cell-specific IFNAR deletion (Ifnar1fl/fl CD4Cre) and
their respective negative littermate controls (Ifnar1fl/fl). The ana-
lyzed groups developed disease with a similar incidence and
a comparable mean disease onset and severity (Figure 5, Table
S3). Notably, there were 3 days during the priming phase in
which T cell-specific Ifnar1/ mice had a higher clinical score
(p < 0.05, Figure 5B). Spinal cord sections, however, revealed
a comparable amount of macrophages and microglia and T lym-
phocytes in Ifnar1fl/fl CD4Cre mice (Figure 5C). Accordingly,
myelin damage was similar in this line.
To determine whether loss of IFNAR on T cells had an overall
impact on antigen (Ag)-driven responses, we immunized mice
with either MOG35–55 peptide or keyhole limpet haemocyanine
(KLH) emulsified in complete freund adjuvant (CFA) and as-
sessed the capacity of lymphocytes to respond to their cognate
Ag in a recall assay. Lymphocytes from Ifnar1fl/fl CD4Cre mice
developed comparable proliferative responses and produced
similar amounts of encephalitogenic IL-17 (Figures 5D and 5E).
In addition, in Ifnar1fl/fl CD4Cre mice, CNS-infiltrating T lympho-
cytes revealed unchanged amounts of the activation markers
CD62L and CD44 (Figure 5F). These results clearly demonstrated
that IFNAR triggering of T cells had no impact on the induction
and progression of CNS autoimmunity.
Because B cells also carry the IFNAR (Pogue et al., 2004), B
cell-specific Ifnar1/ mice (Ifnar1fl/fl CD19Cre) and their respec-
tive littermate controls (Ifnar1fl/fl) were challenged with MOG in
CFA. No clinical differences were observed between the groups
regarding their clinical parameters Figure S3, Table S3). As
expected, concomitant CNS pathology was similar in terms of
distribution as well as amount of infiltrating macrophages, T lym-
phocytes, and demyelination (Figure S3C).
To test whether B cells could produce antigen-specific IL-10
in the absence of IFNAR, we purified splenic B cells from mice
that were in the effector phase of EAE. To ensure B cell-receptor
crosslinking, we coated tissue-culture wells with MOG3555
before adding the purified B cells. B cells incubated with the an-
tigen alone did not produce IL-10. Addition of an agonistic CD40
antibody to the cultures, however, resulted in production of
IL-10, which could be further increased in combination with the
MOG antigen (Figure S3D). Notably, this B cell-specific IL-10
production was independent of the presence of IFNAR. Taken
together, these results clearly show that IFNAR engagement
on lymphocytes by endogenous type I IFN had no impact on
EAE development.
Distinct and Nonredundant In Vivo Functions
of IFNAR on Myeloid Cells Determine Disease Course
Myeloid cells are potential targets for endogenously produced
IFN-b and might therefore function as cells limiting disease dur-
ing CNS autoimmunity. To address this question experimentally,
we first analyzed Ifnar1fl/fl LysMCre mice for cell specificity of
IFNAR deletion (Figure 6A, Figures S2A and S4). As expected,
CD11b+ cells showed a strong deletion of IFNAR on both the
DNA and protein level. Because the LysM Cre transgene is po-
tentially expressed in many myeloid cell types, we characterized
IFNAR depletion in specific CD11b+ subsets (Figure S2B). WeImmunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 677
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IFNAR and CNS AutoimmunityFigure 2. IFNAR Signaling Is Critical for the Effector Phase of Disease, CNS Pathology, and the Induction of Myeloattractants
(A) EAE was induced by active immunization of Ifnar1+/+ (open squares) and Ifnar1/ (filled circles) mice, and disease was scored as described in the Experi-
mental Procedures. Each data point represents the mean of at least seven animals. Statistically significant data points are marked with asterisks (p < 0.05).
(B and C) Characterization of infiltrates and demyelination in IFNAR-deficient mice. (B) shows histology of spinal cord sections with CD3 for T lympho-
cytes, MAC-3 for macrophages, and luxol fast blue (LFB) for demyelination (scale bar represents 200 mm). (C) shows quantification of demyelination678 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.
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IFNAR and CNS Autoimmunityfound substantial IFNAR deletion on CD11b+Ly-6Clo resident
monocytes (r monocytes) as well as on CD11b+Ly-6Chi inflam-
matory blood monocytes (i monocytes) but importantly not
on CD11c+CD11bB220+ plasmacytoid dendritic cells (pDCs)
or CD11c+CD11b+B220 myeloid DCs (mDCs). CD11b+Gr-1+
granulocytes, however, revealed an IFNAR deletion as well.
Notably, deletion of IFNAR led to a strong decrease of phosphor-
ylated STAT1 protein in CD11b+ splenocytes upon stimulation
with IFN-b in Ifnar1fl/fl LysMCre cells compared to WT CD11b+
cells (Figure S2C).
After immunization of mice, a similar disease onset with a dis-
ease incidence comparable to WT mice was observed (Fig-
ure 6B, Table S3). Surprisingly, clinical disease was clearly ag-
gravated during the effector phase in Ifnar1fl/fl LysMCre mice,
leading to a lethality rate of 33%, whereas all Ifnar1fl/fl mice sur-
vived (p < 0.05). Accordingly, the mean clinical score was signif-
icantly higher in Ifnar1fl/fl LysMCre animals (p < 0.05, Figure 6B,
Table S3). The phenotype of this line largely mirrors the disease
course seen in Ifnar1/ mice. Importantly, the generation of en-
cephalitogenic MOG-specific T lymphocytes was unaltered even
at early time points in Ifnar1fl/fl LysMCre mice, indicating that
LysM expressing IFNAR+ cells were not essential for priming
(Figure 6C, Figure S5).
We next used quantitative real-time PCR analysis to determine
the expression of proinflammatory mediators in the CNS of mye-
loid cell-specific Ifnar1/mice at the peak of disease (Figure S6).
Among factors tested, CCL2 and TNFa were upregulated in the
CNS of IFNARfl/fl LysMCre animals. We further measured sur-
face marker expression on CNS infiltrating CD11b+ cells. We
found more MHC class II-expressing CD11b+ cells in the CNS
Figure 3. Encephalitogenic T Cells Are More Effective at Inducing
EAE When Transferred into IFNAR-Deficient Hosts
Clinical score over time after adoptive transfer of MOG-reactive T cells into
Ifnar1/ (filled circles) or Ifnar1+/+ (open squares). Data shown are from one
representative experiment of three individual experiments with at least five
mice per group. Asterisks indicate statistical significance (p < 0.05).showing either Ly-6Chi or Ly-6Clo expression and CD45hi or
CD45lo, indicating the involvement of several myeloid MHC class
II+ cell types (Figure 6D).
In order to clarify whether engagement of IFNAR on macro-
phages and microglia modulates CNS pathology, we measured
the amount of degraded myelin protein (dMBP) in MAC-3+
macrophages and microglia and found significantly increased
numbers of deposits in the absence of IFNAR (Figure 6E). To
test further whether IFNs can change the uptake of myelin
by macrophages, we challenged isolated macrophages with
IFN-b in vitro (Figure 6F). We found that exogenously added
IFN-bwas able to modulate myelin uptake by macrophages. My-
elin uptake was significantly reduced after incubation with IFN-b,
indicating that IFNAR-mediated signaling is a regulator of myelin
phagocytosis on cellular level. Further, exogenously added IFN-
b revealed impaired MHC class II downregulation in IFN-g-stim-
ulated Ifnar1/ macrophages that was largely dependent on the
presence of Tyk2, a member of the Jak family kinases known to
be crucial for the receptor signal transduction by IFNs (Fig-
ure 6G).
To determine how the lack of IFNAR on myeloid cells shapes
the immune profile of macrophages, we tested the chemokine
pattern in response to the IFN-b inducer LPS alone and in com-
bination with IFN-b (Figure S7). However, when LPS was com-
bined with IFN-b, CXCL1 and CXCL2 production was modulated
in WT but not Ifnar1fl/fl LysMCre macrophages, suggesting that
the absence of IFNAR on myeloid cells can cause an enhanced
chemokine response.
Microglia, the brain-endogenous macrophages, might also
be targeted with LysMCre transgenic mice and could therefore
also contribute to the IFN-mediated suppression of CNS auto-
immunity. Indeed, by performing Southern-blot analysis, we ob-
served a substantial deletion in hematopoietic microglia,
whereas neuroectodermal astrocytes were devoid of homolo-
gous recombination in the presence of the Cre transgene
(Figure 7A). Importantly, further in vivo examinations revealed
that in the absence of IFNAR signaling, CD11b+Ly-6loCD45lo
microglia were a major population within the CNS that ex-
pressed MHC class II molecules during EAE (Figure 7B).
Moreover, Ifnar1fl/fl LysMCre microglia isolated from the CNS
exhibited an altered CXCL2 production capacity in vitro upon
LPS stimulation (Figure 7C), thereby potentially contributing to
the phenotype observed.
Absence of a T Cell-Related Transcription Profile
in Microglia upon IFN-b Challenge
To better understand how type 1 IFNs modulate the macrophage
immune responses in general, we challenged microglia with
IFN-b and investigated the IFN-induced transcriptional profiling.
Cells were treated with IFN-b for 6 and 24 hr, and an Affymetrix
Mouse Genome 430A 2.0 array was performed. The statistical(left) and infiltration (right). Each symbol indicates mean of one mouse. Data are expressed as mean ± SEM. Significant differences are marked with
asterisks.
(D) Enzyme-linked immunospot analysis of IFN-g, IL-4, and IL-17 production by lymph node and CNS-derived MOG-reactive lymphocytes restimulated
for 48 hr with MOG35–55.
(E) Expression of chemokines at peak of disease (above) and Th1, Th2, and Th17 cell related factors during different disease stages (10, 18, and 30 days after
immunization) (below) in the CNS of Ifnar1/ (black symbols) or WT (white symbols) mice. Data are expressed as ratio of induced factors versus endogenous
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as mean ± SEM. Significant differences are marked with asterisks.Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 679
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IFNAR and CNS AutoimmunityFigure 4. Brain-Specific IFNAR Expression Is Dispensable for the Autoimmune Process within the CNS
(A) Southern-blot analysis of different tissues from Ifnar1fl/fl NesCre mice. Deletion band (4.1 kb) and WT band (5.0 kb) are shown.
(B) Clinical course of EAE in Ifnar1fl/fl NesCre mice (filled circles) compared to the WT (open squares). One representative experiment out of two is shown.
(C) Histopathology of spinal cords visualized by MAC-3 for macrophages and by CD3 for T cells (left) and quantification thereof (right).
(D–F) CNS pathology in Ifnar1fl/fl NesCre animals. (D) shows distribution (left) and quantity (right) of amyloid precursor protein (APP) deposits representing axonal
damage. (E) shows regions (left) and extent (right) of demyelination (luxol fast blue [LFB]). (F) shows the appearance and number of activated glial fibrillary acidic
protein-positive (GFAP) astrocytes in the spinal cord during disease. Data are expressed as mean ± SEM (nR 5).
Scale bars represent 100 mm in (C)–(F).procedures allowed the identification of 663 significantly regu-
lated genes that were submitted to a k-means clustering analysis
with R. This objective method allowed the detection of four dif-
ferent groups of gene induction with clusters 1, 2, and 4 that
showed upregulated genes and cluster 3 with downregulated
genes (Figure 7D).
We used the 533 upregulated genes from clusters 1, 2, and 4 for
a functional analysis of overrepresentation of Gene Ontology
terms in thisgenes by theGOstatspackage for R (FalconandGen-
tleman, 2007). The most significant functional group of genes was680 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.found to lie within immune or host defense response rather than in
the induction of Th1, Th2, or Th17 cell genes. Independent of the
gene clustersdiscussedabove, in Table S4, themostsubstantially
upregulated genes after 6 or 24 hr are shown grouped according
to their biological function. Most importantly, many chemokines,
cytokines, costimulatory, antigen-presentation molecules, and
macrophage-related activation markers were strongly upregu-
lated, whereas no overt upregulation of genes indicative for a Th
cell shift were detectable, suggesting a primary innate immune
response of macrophages upon IFN-b challenge.
Immunity
IFNAR and CNS AutoimmunityTaken together, our data indicate that engagement of myeloid-
specific IFNAR by endogenously produced IFN-b modulates the
effector but not the priming phase of EAE and leads to aggra-
vated autoimmunity by shaping the innate immune response of
myeloid cells, e.g., cytokine and chemokine production, expres-
sion of surface immune receptors, and myelin phagocytosis.
DISCUSSION
We addressed here the function of the receptor of type I inter-
ferons (IFNAR) in an autoimmune inflammatory mouse model
of MS where disease-associated IFN-b is produced locally in the
CNS. By using gene-targeted mice, we were able to investigate
the role of ubiquitously expressed IFNAR specifically on brain
cells as well as on other cell types that participate in EAE patho-
genesis, including T and B lymphocytes as well as macrophages
and granulocytes. This approach allowed us to identify in vivo
the main cell type targeted by interferon action that essentially
contributes to CNS autoimmunity.
We found that IFN-b is produced locally in the CNS, but not
in the blood, during inflammatory demyelination and that IF-
NAR-dependent genes show disease-associated upregulation.
Although many cell types are capable of producing type 1 inter-
ferons during infection and autoimmunity, the main producers
are thought to be plasmacytoid dendritic cells in the blood (Asse-
lin-Paturel et al., 2001; Ito et al., 2006). However, brain-endoge-
nous cells, e.g., microglia, astrocytes, and neurons, have been
shown to produce IFN-b as well (Delhaye et al., 2006; Town
et al., 2006). It has been described that plasmacytoid DCs, con-
Figure 5. T Cell-Mediated IFNAR Signaling
Is Not Required for the Effector Phase of
EAE Disease
(A) Genomic Southern-blot analysis of several tis-
sues from Ifnar1fl/fl CD4Cre animals.
(B) Disease course in Ifnar1fl/fl CD4Cre (filled cir-
cles) and WT mice (open squares). One represen-
tative experiment out of two is shown. Asterisks
indicate statistical significance.
(C) Quantity of infiltrates at 35 days after immuni-
zation. Sections were stained with MAC-3 for
macrophages and microglia, CD3 for lympho-
cytes, and luxol fast blue (LFB) for myelin. The
scale bar represents 200 mm.
(D and E) Recall responses of Ifnar1fl/fl CD4Cre
(filled circles) and WT (open squares) lymph node
cells to either MOG35–55 peptide or KLH at several
dosages were measured by [H]thymidine-uptake
(D) and IL-17 ELISA (E). Shown are representative
of two independent experiments.
(F) Activation status of CNS-infiltrating T cells dur-
ing autoimmune inflammation of the CNS (gated
on CD4 cells).
ventional DCs, and CD8 alpha+ DCs do
invade during acute relapsing EAE in-
duced by a proteolipid protein peptide
of amino acids 178–191 (Miller et al.,
2007). Nevertheless, the cellular source
of disease associated IFN-b production
within in the CNS remains to be determined in our MOG35–55
EAE model.
In order to test the functional significance of the IFNAR system
in the EAE model, we immunized mice lacking IFNAR from all tis-
sues. Importantly, these mice showed an intensified effector
phase with increased rate of lethality accompanied by aggra-
vated neuropathological changes, consisting of elevated num-
bers of invading macrophages and stronger demyelination. De-
spite higher local production of chemoattractants within the
CNS, the number of infiltrating mononuclear cells in the preclin-
ical phase and the ratio of Th cell cytokines remained un-
changed. Some results are consistent with a previous observa-
tion that mice lacking one ligand of IFNAR, namely IFN-b,
developed a more severe MBP89–101-induced EAE (Teige et al.,
2003), but in contrast to these earlier findings, we could not de-
tect a substantial increase of the Th1 cell cytokine IFN-g within
the CNS of affected mice. Further, our results from the transfer
EAE experiments revealed that antigen-restimulated T cells
from WT mice induced significantly more disease in IFNAR-defi-
cient animals, indicating that IFNAR expression on host-derived
cells is critical for disease induction.
We applied the Cre-LoxP technique to identify the pathogenic
role of neuroectoderm-derived CNS host cells, namely astro-
cytes, oligodendrocytes, and neurons, during EAE. Although it
has been shown that astrocytes and oligodendrocytes have
proinflammatory properties under several conditions (van Loo
et al., 2006), our results strongly indicate that brain-restricted
IFNAR expression does not contribute to the pathogenesis of
EAE. Our data are unexpected because previous reports pointedImmunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 681
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IFNAR and CNS AutoimmunityFigure 6. IFNAR Signaling on Peripheral Myeloid Cells Regulates Effector Phase of Autoimmune Encephalomyelitis by Limiting Cell Activa-
tion
(A) Tissue-restricted deletion of the floxed IFNAR locus is shown by Southern-blot analysis in Ifnar1fl/fl LysMCre mice. MACS-sorted splenic CD11b+ cells were
used as positive control. Deletion band (4.1 kb) and WT band (5.0 kb) are shown.
(B) Disease course in the absence of IFNAR on macrophages and neutrophiles. Statistically significant time points are marked with asterisks (p < 0.05). The results
are representative of five independent experiments.682 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.
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IFNAR and CNS Autoimmunitytoward a modulating role of IFN-b on astrocytes (Okada et al.,
2005; Teige et al., 2006) and oligodendrocytes (Passaquin
et al., 1989; Mastronardi et al., 2004). Despite the fact that our re-
sults clearly rule out a disease-modulating role for IFNAR on neu-
roectodermal cells during EAE, it is still possible that this IFNAR
expression might be more important in chronic relapsing EAE
models.
EAE is a T cell-mediated disease, and it has been reported that
IFNAR is expressed on lymphocytes, as well (Pogue et al., 2004).
However, in our study, T cell-restricted Ifnar1/ mice developed
a similar course of EAE with comparable neuropathological
changes. Furthermore, we could not detect any differences in
Figure 7. CNS-Endogenous Microglia Have
a Changed Immune Pattern in the Absence
of IFNAR during EAE
(A) Southern-blot analysis of Ifnar1fl/fl LysMCre mi-
croglia and astrocytes. Deletion band (4.1 kb) and
WT band (5.0 kb) are shown.
(B) FACS of MHC class II molecules on CD11b+Ly-
6CloCD45lo microglia in the CNS of diseased
animals.
(C) CXCL2 production of IFNAR-deficient micro-
glia (Ifnar1fl/fl LysMCre, white bars) and negative
littermates (black bars) upon costimulation with
LPS and IFN-b. Data represent mean ± SEM
(nR 6).
(D) Gene induction pattern of all 663 significantly
regulated genes after IFN-b challenge in microglia
with a k-means cluster analysis to identify specific
cohorts of gene induction. Clusters are defined by
different gene regulation over time. Numbers in-
dicate the quantity of regulated genes within the
respective cluster.
the effector function of T cells because
MOG35–55-specific T lymphocytes pro-
duced equivalent amounts of IFN-g, IL-
17, and IL-4 and proliferated similarly in
the absence of IFNAR. In addition, sur-
face expression of activation markers
CD62L and CD44 of brain infiltrating T
lymphocytes was not influenced by the
absence or presence of IFNAR. Hence,
our findings do not support the idea that
endogenously produced IFN-b acts ben-
eficially on T cells, either through inhibit-
ing T cell proliferation or through skewing
the T cell-cytokine response.
The immune-modulatory function of B cells has been de-
scribed in the context of EAE, and it is feasible that type I IFNs
modulate their regulatory function (Fillatreau et al., 2002). Yet,
our analysis of B cell-restricted Ifnar1/ mice revealed an unal-
tered course of disease with normal infiltrates and typical demy-
elination, thus disproving a functional role of IFNAR on B cells for
the pathogenesis of EAE. The absence of IFNAR on B cells does
not affected MOG-specific IL-10 production by B cells, showing
again the normal B cell function in IFNAR-deficient mice.
In order to test the hypothesis that IFNAR engagement on my-
eloid cells is crucial in modulating CNS autoimmunity, we took
advantage of the LysM Cre transgenic mouse. Notably, the(C) Priming of MOG-specific T lymphocytes at different time points of disease in lymph nodes of Ifnar1fl/fl LysMCre (filled circles) or WT (open symbols) mice. cpm
indicates counts per minute. Data represent mean ± SEM.
(D) Characterization of CNS-infiltrating CD11b+ MHC class II+ myeloid cells (left) during peak of disease in Ifnar1/ mice. These cells exhibited Ly-6Chi and
Ly-6Clo and CD45hi and CD45lo expression patterns.
(E) Accumulation of degraded myelin protein (dMBP, black arrows) in MAC-3+ macrophages (red) in the absence of IFNAR (left) and quantification thereof (right) in
EAE diseased CNS tissue. Significant differences are marked with an asterisk. The scale bar represents 15 mm.
(F) Modulation of myelin uptake by IFN-b. Macrophages ingested fluorescein isothiocyanate (FITC)-labeled myelin (green) in lysosomal compartments (red, left
panel). Myelin uptake in the presence of external IFN-b (black bars) or cytochalasin D (gray bars, right panel) is shown. One experiment out of four is shown.
Significant differences are marked with asterisks. The scale bar represents 5 mm.
(G) Aberrant MHC class II regulation on cultured peritoneal Ifnar1/ macrophages in the absence of Tyk2. Cells were stimulated with either IFN-b (black lines)
or IFN-g (green lines) alone or combination of both (red lines). Inhibition of IFN-g-induced MHC II production by IFN-b in WT, IFNAR/, and Tyk2/ cells (right).
**: p < 0.01, *: p < 0.05.Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 683
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mice was strongly increased during the effector phase, and
some mice even died because of severe disease. The clinical dif-
ferences to control mice, however, were not always statistically
relevant, as seen in the total Ifnar1/ situation, most likely due
to the fact that gene deletion in myeloid cells is incomplete (Gri-
vennikov et al., 2005). Which myeloid cell types are crucial in the
IFNAR-mediated change of CNS autoimmunity? Although gran-
ulocytes have been shown to have immunoregulatory capacity
during EAE development (Zehntner et al., 2005), their number
was, in contrast to MAC-3+ mononuclear phagocytes, quite
low and not elevated in the CNS (data not shown). The MAC-3
antigen can be found on tissue macrophages, thioglycollate-eli-
cited peritoneal macrophages, and monocytes (Walker et al.,
1985), suggesting that these cells might shape the immmune re-
sponse within in the CNS. Both CD11b+Ly-6Chi and CD11b+Ly-
6Clo monocytes were found to be targeted by the LysM Cre
transgene, and therefore these cells might task as endogenous
type I interferon-dependent modulators of CNS autoimmunity
from the peripheral site. Importantly, professional antigen-
presenting cells (APCs) such as plasmacytoid DCs or myeloid
DCs were not targeted by the LysM Cre transgene, disproving
a role of IFNAR on these cell subsets during sterile autoimmunity
of the CNS.
Microglia cells are another possible candidate that could
suppress inflammatory demyelination in a type I-interferon-de-
pendent manner. They are the brain-endogenous macrophages
and populate the CNS early during development to form a regu-
larly spaced network of ramified cells (Priller et al., 2001). Micro-
glia become rapidly activated in most pathological conditions of
the CNS. In autoimmune diseases such as multiple sclerosis,
most experimental results point to a detrimental role of microglia;
for example, then can produce neurotoxic molecules, proinflam-
matory cytokines, and chemokines and can present self-anti-
gens (Steinman, 1996). How could type I interferons modulate
microglia-mediated damage in EAE? Nitric oxide (NO) and its ad-
ducts may disrupt CNS tissue integrity (Steinman et al., 2002),
whereas microglia-derived cytokines and chemokines such as
TNF and CXCL2 activate and attract blood-derived leukocytes.
These may in turn interfere with CNS homeostasis (e.g., by dam-
aging myelin) (Steinman et al., 2002; Hanisch, 2002). However,
effects of IFN-b on production of proinflammatory mediators,
such as TNFa, IL-1, or NO, are controversial and seem to be
dependent on the mode and conditions of activation (Jin et al.,
2007). Further, reactivation of myelin-specific T cells within the
CNS upon recognition of local autoantigens is critical to induce
and/or sustain EAE. But it is still debated whether and to what ex-
tent microglia present myelin-associated antigens to autoreac-
tive T cells in vivo (Ford et al., 1995). In vitro, however, it has
been demonstrated that IFN-b exerts its beneficial effects also
by reducing the antigen-presenting capacity of CNS-specific
APCs such as microglia, which in turn inhibits the effector func-
tions of encephalitogenic T cells (Teige et al., 2006). Interestingly,
the lack of IFNAR on CD11b+ myeloid cells did not changed the
Th cell polarization of T cells in our settings, suggesting that other
mechanisms apart from antigen presentation might be vital.
Thus, monocytes and macrophages and their brain-specific
equivalent, the microglia, are the IFNAR-dependent myeloid
cells critical in shaping CNS autoimmunity. IFNAR signaling in684 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.these cells potentially modulates, for example, their activation
state. We found a clear increase of MHC class II molecules in
the absence of IFNAR, indicating hyperactivation of these cells.
These data are in line with previous reports describing a role of
IFN-b for MHC class II expression on monocytes in vitro (Kato
et al., 1992; Li et al., 1998).
Our data might provide unique insights into disease-limiting
mechanisms of autoimmune inflammation, which might open
new avenues toward more cell-specific IFN-b-based therapies
that probably would reduce the severity of side effects.
EXPERIMENTAL PROCEDURES
Mice
Ifnar1/ mice (Muller et al., 1994) originally provided by R. M. Zinkernagel
(Zurich, Switzerland) were backcrossed 20 times to C57BL/6. Mice carrying
loxP-flanked IFNAR (Kamphuis et al., 2006) were crossed with transgenic
mice expressing Cre recombinase under the control of the nestin (Tronche
et al., 1999), CD4 (Wolfer et al., 2001), CD19 (Rickert et al., 1997), or LysM
(Clausen et al., 1999) promoter, each backcrossed at least ten times to
C57BL/6. All mice were bred in house under pathogen-free conditions.
Induction of EAE
Female 6- to 10-week-old mice from each group were immunized subcutane-
ously with 200 mg of MOG35–55 peptide emulsified in CFA containing 1 mg of
Mycobacterium tuberculosis (H37RA; Difco Laboratories, Detroit, MI). The
mice received intraperitonal injections with 250 ng pertussis toxin (Sigma-
Aldrich, Deisenhofen, Germany) at the time of immunization and 48 hr later.
Adoptive transfer was performed as described (Becher et al., 2001; Prinz
et al., 2006). All animal experiments have been approved by the ethics review
board for animal studies at the University of Go¨ttingen.
Clinical Evaluation
Mice were scored daily as follows: 0, no detectable signs of EAE; 0.5, distal
limb tail; 1.0, complete limb tail; 1.5, limb tail and hind-limb weakness; 2,
unilateral partial hind-limb paralysis; 2.5, bilateral partial hind-limb paralysis;
3, complete bilateral hind-limb paralysis; 3.5, complete hind-limb paralysis
and unilateral forelimb paralysis; 4, total paralysis of forelimbs and hind limbs;
and 5, death.
Histology
Mice were sacrificed with CO2. Histology was performed as described recently
(Prinz et al., 2006; van Loo et al., 2006). Spinal cords were removed and fixed in
4% buffered fomalin. Then, spinal cords were dissected and embedded in
paraffin before staining with hematoxylin eosin (H&E) or luxol fast blue (LFB)
to assess the degree of demyelination, MAC-3 (BD PharMingen) for macro-
phages and microglia, CD3 for T cells (Serotec, Du¨sseldorf, Germany), APP
for amyloid precursor protein (Chemicon, Temecula, CA), chloracetate ester-
ase for polymorphonuclear granulocytes (Sigma-Aldrich, Munich Germany),
dMPB for degraded myelin basic protein (Chemicon, Temecula, CA), and
GFAP for astrocytes (Dako, Hamburg, Germany).
RNA
Spinal cord tissue was freshly isolated and RNA isolated with TRI-Reagent
(Sigma) according to the manufacturer’s protocol. RNA (10 mg/lane) was sep-
arated on 1% formaldehyde-agarose gels and blotted to positively charged
nylon membrane. Probes were radioactively labeled with Rediprime (Amer-
sham) and hybridized with Express-Hyb-Solution (Clontech) according to the
manufacturer’s protocol.
Flow Cytometry
The cells were stained with primary antibodies directed against Ly-6C, CD45,
CD44, MAR1-5A3, CD62L, MHC class II, CD11b, CD4, P-STAT-1, and B220
for 30 min at 4C. The cells were washed and analyzed with a FACSCalibur
(Becton Dickinson). Viable cells were gated by forward and side scatter of
light. Data were acquired with CellQuest software (Becton Dickinson).
Immunity
IFNAR and CNS AutoimmunityPostacquisition analysis was perfomed with WinMDI 2.8 software (Scripps-
Research Institute).
Recall Responses, B Cell Activation Assay, IFN-bMeasurements,
and ELISPOT Analysis
Recall assays were performed as described recently (Prinz et al., 2006). For cy-
tokine analysis, sister cultures were harvested 4 hr after culture supernatants
were analyzed by ELISA for IFN-g and IL-17 (R&D Systems, Bergisch-Glad-
bach, Germany).
Spinal cord homogenates were prepared and diluted 1:5 in lysis buffer as
described by us (Prinz and Hanisch, 1999), and IFN-b levels were measured
by application of an IFN-bELISA according to the instructions (PBL Biomedical
Laboratories, New Brunswick, NJ). B cell activation was determined as
described recently by Fillatreau (Fillatreau et al., 2002). Enzyme-linked immu-
nospot analysis was performed as reported previously by us (Gutcher et al.,
2006).
Peritoneal Macrophages, Microglia, and Stimulation
Mice were injected with thioglycolate (29 g/l phosphate-buffered saline [PBS])
intraperitoneally (i.p.). Peritoneal cells were collected 96 hr after injection by la-
vage of the peritoneal cavity with 2 ml of ice-cold PBS. Cells were plated in cell-
culture plates and nonadhering cells were removed by washing of the wells
1 hr later. Microglia were prepared as described (Prinz and Hanisch, 1999).
Macrophages and microglia were incubated for 24 hr prior to experiments
and stimulated with LPS (10 ng/ml), IFN-b (10 ng/ml), and TNFa (10 ng/ml)
for 18 hr. Protein levels were detected by ELISA as described by the manufac-
turer (R&D Systems, Bergisch-Gladbach).
Real-Time PCR and Microarray Analysis
RNA was extracted from tissues and flushed with ice-cold HBSS, and RNA
was isolated with RNAeasy Mini kits (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions. The samples were treated with DNaseI
(Roche, Mannheim, Germany), and 1 mg of RNA was transcribed into comple-
mentary DNA (cDNA) with oligo-dT primers and the SuperScript II RT kit (Invi-
trogen, Carlsbad, CA). cDNA (2.5 ml) was transferred into a 96-well Multiply
PCR-plate (Sarstedt, Germany), and 12.5 ml ABsolute QPCR SYBR Green
master mix (ABgene, Surrey, UK) plus 19.6 ml ddH2O was added. The PCR re-
action was performed as described recently (Prinz et al., 2006; Mildner et al.,
2007).
Total RNA (1 mg) was processed with the MessageAmp II-Biotion Enhanced
Kit (Ambion) and hybridized to the murine array 430 A2.0 according to the
manufacturer’s protocols (Affymetrix). Microarrays were scanned and initially
analyzed with Affymetrix GCOS software. Two biological replicates per condi-
tion (0 hr, 6 hr, and 24 hr IFN-b) were carried out. CEL files were processed for
global normalization, and expression values were generated with the robust
multichip average (rma) algorithm in the R affy package (Bolstad et al.,
2003). So that differential expression could be tested for, the bayesian-ad-
justed t statistics from the linear models for Microarray data (limma) package
with subsequent multiple testing correction based on Benjamini-Hochberg
was used (Hochberg and Benjamini, 1990). Probe sets were considered to
be differentially expressed if there was a minimum n-fold change of 3 between
any of the three conditions and the p value for 6 hr or 24 hr was below 0.01.
SUPPLEMENTAL DATA
Seven figures, four tables, and two movies are available at http://www.
immunity.com/cgi/content/full/28/5/675/DC1/.
ACKNOWLEDGMENTS
We thank O. Kowatsch, D. Kreuz, and E. Pralle for excellent technical assis-
tance. We are grateful to R.D. Schreiber, St. Louis, for generous supply of
the MAR1-5A3 antibody and to T. Decker, Vienna, for Tyk-2-deficient mice.
Gemeinnu¨tzige Hertie-Stiftung supported M.P. German Research Council
(DFG, SFB432, B15) and the Volkswagen Foundation supported U.K. This
work was supported by generous research grants from Biogen Idec and Merck
Serono to M.P. H.S. and A.M. are fellows of the Gertrud Reemtsma foundation.Received: October 9, 2007
Revised: January 27, 2008
Accepted: March 4, 2008
Published online: April 17, 2008
REFERENCES
Asselin-Paturel, C., Boonstra, A., Dalod, M., Durand, I., Yessaad, N., Dezutter-
Dambuyant, C., Vicari, A., O’Garra, A., Biron, C., Briere, F., et al. (2001). Mouse
type I IFN-producing cells are immature APCs with plasmacytoid morphology.
Nat. Immunol. 2, 1144–1150.
Becher, B., Durell, B.G., Miga, A.V., Hickey, W.F., and Noelle, R.J. (2001). The
clinical course of experimental autoimmune encephalomyelitis and inflamma-
tion is controlled by the expression of CD40 within the central nervous system.
J. Exp. Med. 193, 967–974.
Bolstad, B.M., Irizarry, R.A., Astrand, M., and Speed, T.P. (2003). A compari-
son of normalization methods for high density oligonucleotide array data
based on variance and bias. Bioinformatics 19, 185–193.
Brod, S.A., and Burns, D.K. (1994). Suppression of relapsing experimental
autoimmune encephalomyelitis in the SJL/J mouse by oral administration of
type I interferons. Neurology 44, 1144–1148.
Brod, S.A., and Khan, M. (1996). Oral administration of IFN-alpha is superior
to subcutaneous administration of IFN-alpha in the suppression of chronic re-
lapsing experimental autoimmune encephalomyelitis. J. Autoimmun. 9, 11–20.
Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. (1999).
Conditional gene targeting in macrophages and granulocytes using LysMcre
mice. Transgenic Res. 8, 265–277.
Delhaye, S., Paul, S., Blakqori, G., Minet, M., Weber, F., Staeheli, P., and
Michiels, T. (2006). Neurons produce type I interferon during viral encephalitis.
Proc. Natl. Acad. Sci. USA 103, 7835–7840.
Falcon, S., and Gentleman, R. (2007). Using GOstats to test gene lists for GO
term association. Bioinformatics 23, 257–258.
Fillatreau, S., Sweenie, C.H., McGeachy, M.J., Gray, D., and Anderton, S.M.
(2002). B cells regulate autoimmunity by provision of IL-10. Nat. Immunol. 3,
944–950.
Floris, S., Ruuls, S.R., Wierinckx, A., van der Pol, S.M., Dopp, E., van der
Meide, P.H., Dijkstra, C.D., and De Vries, H.E. (2002). Interferon-beta directly
influences monocyte infiltration into the central nervous system. J. Neuroim-
munol. 127, 69–79.
Ford, A.L., Goodsall, A.L., Hickey, W.F., and Sedgwick, J.D. (1995). Normal
adult ramified microglia separated from other central nervous system macro-
phages by flow cytometric sorting. Phenotypic differences defined and direct
ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells
compared. J. Immunol. 154, 4309–4321.
Frohman, E.M., Racke, M.K., and Raine, C.S. (2006). Multiple sclerosis–the
plaque and its pathogenesis. N. Engl. J. Med. 354, 942–955.
Gold, R., Linington, C., and Lassmann, H. (2006). Understanding pathogenesis
and therapy of multiple sclerosis via animal models: 70 years of merits and cul-
prits in experimental autoimmune encephalomyelitis research. Brain 129,
1953–1971.
Grivennikov, S.I., Tumanov, A.V., Liepinsh, D.J., Kruglov, A.A., Marakusha,
B.I., Shakhov, A.N., Murakami, T., Drutskaya, L.N., Forster, I., Clausen, B.E.,
et al. (2005). Distinct and nonredundant in vivo functions of TNF produced
by t cells and macrophages/neutrophils: Protective and deleterious effects.
Immunity 22, 93–104.
Gutcher, I., Urich, E., Wolter, K., Prinz, M., and Becher, B. (2006). Interleukin
18-independent engagement of interleukin 18 receptor-alpha is required for
autoimmune inflammation. Nat. Immunol. 7, 946–953.
Hanisch, U.K. (2002). Microglia as a source and target of cytokines. Glia 40,
140–155.
Heine, S., Ebnet, J., Maysami, S., and Stangel, M. (2006). Effects of interferon-
beta on oligodendroglial cells. J. Neuroimmunol. 177, 173–180.
Hochberg, Y., and Benjamini, Y. (1990). More powerful procedures for multiple
significance testing. Stat. Med. 9, 811–818.Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc. 685
Immunity
IFNAR and CNS AutoimmunityIto, T., Kanzler, H., Duramad, O., Cao, W., and Liu, Y.J. (2006). Specialization,
kinetics, and repertoire of type 1 interferon responses by human plasmacytoid
predendritic cells. Blood 107, 2423–2431.
Jin, S., Kawanokuchi, J., Mizuno, T., Wang, J., Sonobe, Y., Takeuchi, H., and
Suzumura, A. (2007). Interferon-beta is neuroprotective against the toxicity
induced by activated microglia. Brain Res. 1179, 140–146.
Kamphuis, E., Junt, T., Waibler, Z., Forster, R., and Kalinke, U. (2006). Type I
interferons directly regulate lymphocyte recirculation and cause transient
blood lymphopenia. Blood 108, 3253–3261.
Kato, T., Kitaura, M., Inaba, K., Watanabe, Y., Kawade, Y., and Muramatsu, S.
(1992). Suppression of macrophage Ia antigen expression by endogenous
interferon-alpha/beta. J. Interferon Res. Spec No, 29–41.
Kozovska, M.E., Hong, J., Zang, Y.C., Li, S., Rivera, V.M., Killian, J.M., and
Zhang, J.Z. (1999). Interferon beta induces T-helper 2 immune deviation in
MS. Neurology 53, 1692–1697.
Li, Q., Milo, R., Panitch, H., and Bever, C.T., Jr. (1998). Effect of propranolol
and IFN-beta on the induction of MHC class II expression and cytokine pro-
duction by IFN-gamma IN THP-1 human monocytic cells. Immunopharmacol.
Immunotoxicol. 20, 39–61.
Mastronardi, F.G., Min, W., Wang, H., Winer, S., Dosch, M., Boggs, J.M., and
Moscarello, M.A. (2004). Attenuation of experimental autoimmune encephalo-
myelitis and nonimmune demyelination by IFN-beta plus vitamin B12: Treat-
ment to modify notch-1/sonic hedgehog balance. J. Immunol. 172, 6418–
6426.
McRae, B.L., Semnani, R.T., Hayes, M.P., and van Seventer, G.A. (1998). Type
I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development.
J. Immunol. 160, 4298–4304.
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.K., Mack, M.,
Heikenwalder, M., Bruck, W., Priller, J., and Prinz, M. (2007). Microglia in the
adult brain arise from Ly-6C(hi)CCR2(+) monocytes only under defined host
conditions. Nat. Neurosci. 10, 1544–1553.
Miller, S.D., McMahon, E.J., Schreiner, B., and Bailey, S.L. (2007). Antigen
presentation in the CNS by myeloid dendritic cells drives progression of
relapsing experimental autoimmune encephalomyelitis. Ann. N Y Acad. Sci.
1103, 179–191.
Muller, U., Steinhoff, U., Reis, L.F., Hemmi, S., Pavlovic, J., Zinkernagel, R.M.,
and Aguet, M. (1994). Functional role of type I and type II interferons in antiviral
defense. Science 264, 1918–1921.
Neilley, L.K., Goodin, D.S., Goodkin, D.E., and Hauser, S.L. (1996). Side effect
profile of interferon beta-1b in MS: Results of an open label trial. Neurology 46,
552–554.
Okada, K., Kuroda, E., Yoshida, Y., Yamashita, U., Suzumura, A., and Tsuji, S.
(2005). Effects of interferon-beta on the cytokine production of astrocytes.
J. Neuroimmunol. 159, 48–54.
Owens, T., Wekerle, H., and Antel, J. (2001). Genetic models for CNS inflam-
mation. Nat. Med. 7, 161–166.
Panitch, H.S., Hirsch, R.L., Schindler, J., and Johnson, K.P. (1987). Treatment
of multiple sclerosis with gamma interferon: Exacerbations associated with
activation of the immune system. Neurology 37, 1097–1102.
Passaquin, A.C., Coupin, G., Schreier, W.A., Poindron, P., Cole, R.A., and de
Vellis, J. (1989). Interferon inhibits the accumulation of glycerol phosphate
dehydrogenase mRNA in oligodendrocytes and C6 cells. Neurochem. Res.
14, 987–993.
Pogue, S.L., Preston, B.T., Stalder, J., Bebbington, C.R., and Cardarelli, P.M.
(2004). The receptor for type I IFNs is highly expressed on peripheral blood B
cells and monocytes and mediates a distinct profile of differentiation and
activation of these cells. J. Interferon Cytokine Res. 24, 131–139.
Priller, J., Flu¨gel, A., Wehner, T., Boentert, M., Haas, C.A., Prinz, M.,
Fernandez-Klett, F., Prass, K., Bechmann, I., de Boer, B.A., et al. (2001). Tar-
geting gene-modified hematopoietic cells to the central nervous system: Use
of green fluorescent protein uncovers microglial engraftment. Nat. Med. 7,
1356–1361.686 Immunity 28, 675–686, May 2008 ª2008 Elsevier Inc.Prinz, M., and Hanisch, U.K. (1999). Murine microglial cells produce and
respond to interleukin-18. J. Neurochem. 72, 2215–2218.
Prinz, M., Garbe, F., Schmidt, H., Mildner, A., Gutcher, I., Wolter, K., Piesche,
M., Schroers, R., Weiss, E., Kirschning, C.J., et al. (2006). Innate immunity
mediated by TLR9 modulates pathogenicity in an animal model of multiple
sclerosis. J. Clin. Invest. 116, 456–464.
Rickert, R.C., Roes, J., and Rajewsky, K. (1997). B lymphocyte-specific,
Cre-mediated mutagenesis in mice. Nucleic Acids Res. 25, 1317–1318.
Satoh, J., Paty, D.W., and Kim, S.U. (1995). Differential effects of beta and
gamma interferons on expression of major histocompatibility complex anti-
gens and intercellular adhesion molecule-1 in cultured fetal human astrocytes.
Neurology 45, 367–373.
Satoh, J., Nanri, Y., Tabunoki, H., and Yamamura, T. (2006). Microarray
analysis identifies a set of CXCR3 and CCR2 ligand chemokines as early IFN-
beta-responsive genes in peripheral blood lymphocytes in vitro: An implication
for IFNbeta-related adverse effects in multiple sclerosis. BMC Neurol. 6, 18.
Steinman, L. (1996). Multiple sclerosis: A coordinated immunological attack
against myelin in the central nervous system. Cell 85, 299–302.
Steinman, L. (2007). A brief history of T(H)17, the first major revision in the
T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat. Med. 13,
139–145.
Steinman, L., Martin, R., Bernard, C., Conlon, P., and Oksenberg, J.R. (2002).
Multiple sclerosis: Deeper understanding of its pathogenesis reveals new
targets for therapy. Annu. Rev. Neurosci. 25, 491–505.
Stone, L.A., Frank, J.A., Albert, P.S., Bash, C., Smith, M.E., Maloni, H., and
McFarland, H.F. (1995). The effect of interferon-beta on blood-brain barrier
disruptions demonstrated by contrast-enhanced magnetic resonance imaging
in relapsing-remitting multiple sclerosis. Ann. Neurol. 37, 611–619.
Teige, I., Treschow, A., Teige, A., Mattsson, R., Navikas, V., Leanderson, T.,
Holmdahl, R., and Issazadeh-Navikas, S. (2003). IFN-beta gene deletion leads
to augmented and chronic demyelinating experimental autoimmune encepha-
lomyelitis. J. Immunol. 170, 4776–4784.
Teige, I., Liu, Y., and Issazadeh-Navikas, S. (2006). IFN-beta inhibits T cell
activation capacity of central nervous system APCs. J. Immunol. 177, 3542–
3553.
Town, T., Jeng, D., Alexopoulou, L., Tan, J., and Flavell, R.A. (2006). Microglia
recognize double-stranded RNA via TLR3. J. Immunol. 176, 3804–3812.
Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P.C., Bock,
R., Klein, R., and Schutz, G. (1999). Disruption of the glucocorticoid receptor
gene in the nervous system results in reduced anxiety. Nat. Genet. 23, 99–103.
van Loo, G., De Lorenzi, R., Schmidt, H., Huth, M., Mildner, A., Schmidt-
Supprian, M., Lassmann, H., Prinz, M.R., and Pasparakis, M. (2006). Inhibition
of transcription factor NF-kappaB in the central nervous system ameliorates
autoimmune encephalomyelitis in mice. Nat. Immunol. 7, 954–961.
Walker, E.B., Akporiaye, E.T., Warner, N.L., and Stewart, C.C. (1985). Charac-
terization of subsets of bone marrow-derived macrophages by flow cytometry
analysis. J. Leukoc. Biol. 37, 121–136.
Wandinger, K.P., Sturzebecher, C.S., Bielekova, B., Detore, G., Rosenwald,
A., Staudt, L.M., McFarland, H.F., and Martin, R. (2001). Complex immuno-
modulatory effects of interferon-beta in multiple sclerosis include the upregu-
lation of T helper 1-associated marker genes. Ann. Neurol. 50, 349–357.
Waubant, E., Vukusic, S., Gignoux, L., Dubief, F.D., Achiti, I., Blanc, S.,
Renoux, C., and Confavreux, C. (2003). Clinical characteristics of responders
to interferon therapy for relapsing MS. Neurology 61, 184–189.
Wolfer, A., Bakker, T., Wilson, A., Nicolas, M., Ioannidis, V., Littman, D.R., Lee,
P.P., Wilson, C.B., Held, W., MacDonald, H.R., et al. (2001). Inactivation of
Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell develop-
ment. Nat. Immunol. 2, 235–241.
Zehntner, S.P., Brickman, C., Bourbonniere, L., Remington, L., Caruso, M.,
and Owens, T. (2005). Neutrophils that infiltrate the central nervous system
regulate T cell responses. J. Immunol. 174, 5124–5131.
